Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T

The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change fro

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price

Humacyte, Inc. (HUMA) closed the most recent trading day at $1.03, moving 3.74% from the previous tr

Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access

Humacyte, Inc. (HUMA) might move higher on growing optimism about its earnings prospects, which is r

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered

– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Humacyte (NASDAQ:HUMA) with a Bu

Humacyte (HUMA) stock plummets 22% despite positive Phase 3 ATEV trial data as investors react to a

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage bi

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universal

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage bi

The V012 clinical study is designed to demonstrate the efficacy and safety of the ATEV as a dialysis

- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Ad

Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Jun

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or ob

Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and ra

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Humacyte (NASDAQ:HUMA) with a B

- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually -  -

- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospita

- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospita

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and raises the price

BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price targ

Humacyte NASDAQ: HUMA reported first-quarter 2026 Symvess sales of $0.5 million and outlined a serie

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus E

Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.09) per share which beat the analyst consens

- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Offi

- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership t

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universal

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universa

Barclays analyst Matt Miksic maintains Humacyte (NASDAQ:HUMA) with a Overweight and lowers the pr

Top Wall Street analysts changed outlook on top names. Needham downgrades CNTA, Baird downgrades PHR

Benchmark analyst Bruce D. Jackson downgrades Humacyte (NASDAQ:HUMA) from Buy to Speculative Buy

Piper Sandler analyst Allison Bratzel maintains Humacyte (NASDAQ:HUMA) with a Neutral and lowers

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price

BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price targ

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universa